Surgery for rheumatic heart disease in the Northern Territory, Australia, 1997-2016: what have we gained?
Child health
Public Health
Thoracic surgery
Treatment
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
14
01
2023
accepted:
06
03
2023
medline:
28
3
2023
entrez:
24
3
2023
pubmed:
25
3
2023
Statut:
ppublish
Résumé
Between 1964 and 1996, the 10-year survival of patients having valve replacement surgery for rheumatic heart disease (RHD) in the Northern Territory, Australia, was 68%. As medical care has evolved since then, this study aimed to determine whether there has been a corresponding improvement in survival. A retrospective study of Aboriginal patients with RHD in the Northern Territory, Australia, having their first valve surgery between 1997 and 2016. Survival was examined using Kaplan-Meier and Cox regression analysis. The cohort included 281 adults and 61 children. The median (IQR) age at first surgery was 31 (18-42) years; 173/342 (51%) had a valve replacement, 113/342 (33%) had a valve repair and 56/342 (16%) had a commissurotomy. There were 93/342 (27%) deaths during a median (IQR) follow-up of 8 (4-12) years. The overall 10-year survival was 70% (95% CI: 64% to 76%). It was 62% (95% CI: 53% to 70%) in those having valve replacement. There were 204/281 (73%) adults with at least 1 preoperative comorbidity. Preoperative comorbidity was associated with earlier death, the risk of death increasing with each comorbidity (HR: 1.3 (95% CI: 1.2 to 1.5), p<0.001). Preoperative chronic kidney disease (HR 6.5 (95% CI: 3.0 to 14.0) p≤0.001)), coronary artery disease (HR 3.3 (95% CI: 1.3 to 8.4) p=0.012) and pulmonary artery systolic pressure>50 mm Hg before surgery (HR 1.9 (95% CI: 1.2 to 3.1) p=0.007) were independently associated with death. Survival after valve replacement for RHD in this region of Australia has not improved. Although the patients were young, many had multiple comorbidities, which influenced long-term outcomes. The increasing prevalence of complex comorbidity in the region is a barrier to achieving optimal health outcomes.
Sections du résumé
BACKGROUND
Between 1964 and 1996, the 10-year survival of patients having valve replacement surgery for rheumatic heart disease (RHD) in the Northern Territory, Australia, was 68%. As medical care has evolved since then, this study aimed to determine whether there has been a corresponding improvement in survival.
METHODS
A retrospective study of Aboriginal patients with RHD in the Northern Territory, Australia, having their first valve surgery between 1997 and 2016. Survival was examined using Kaplan-Meier and Cox regression analysis.
FINDINGS
The cohort included 281 adults and 61 children. The median (IQR) age at first surgery was 31 (18-42) years; 173/342 (51%) had a valve replacement, 113/342 (33%) had a valve repair and 56/342 (16%) had a commissurotomy. There were 93/342 (27%) deaths during a median (IQR) follow-up of 8 (4-12) years. The overall 10-year survival was 70% (95% CI: 64% to 76%). It was 62% (95% CI: 53% to 70%) in those having valve replacement. There were 204/281 (73%) adults with at least 1 preoperative comorbidity. Preoperative comorbidity was associated with earlier death, the risk of death increasing with each comorbidity (HR: 1.3 (95% CI: 1.2 to 1.5), p<0.001). Preoperative chronic kidney disease (HR 6.5 (95% CI: 3.0 to 14.0) p≤0.001)), coronary artery disease (HR 3.3 (95% CI: 1.3 to 8.4) p=0.012) and pulmonary artery systolic pressure>50 mm Hg before surgery (HR 1.9 (95% CI: 1.2 to 3.1) p=0.007) were independently associated with death.
INTERPRETATION
Survival after valve replacement for RHD in this region of Australia has not improved. Although the patients were young, many had multiple comorbidities, which influenced long-term outcomes. The increasing prevalence of complex comorbidity in the region is a barrier to achieving optimal health outcomes.
Identifiants
pubmed: 36963786
pii: bmjgh-2023-011763
doi: 10.1136/bmjgh-2023-011763
pmc: PMC10040039
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Am Heart Assoc. 2017 Mar 2;6(3):
pubmed: 28255075
Circulation. 2007 Nov 27;116(22):2634-53
pubmed: 17951284
Med J Aust. 2022 Jul 4;217(1):30-35
pubmed: 35644458
J Thorac Cardiovasc Surg. 2014 Nov;148(5):1996-2003
pubmed: 24629223
Circulation. 2013 Jul 30;128(5):492-501
pubmed: 23794730
Aust J Prim Health. 2018 Mar;24(1):9-13
pubmed: 29310752
J Am Heart Assoc. 2020 Oct 20;9(19):e016851
pubmed: 32924748
PLoS Negl Trop Dis. 2021 Jan 14;15(1):e0008990
pubmed: 33444355
Aust Health Rev. 2022 Jun;46(3):302-308
pubmed: 35508434
Med J Aust. 2021 Mar;214(5):220-227
pubmed: 33190309
Int J Environ Res Public Health. 2019 Nov 06;16(22):
pubmed: 31698685
Cureus. 2020 May 13;12(5):e8094
pubmed: 32542149
JAMA Surg. 2019 Aug 1;154(8):755-766
pubmed: 31054241
Aust N Z J Public Health. 2022 Oct;46(5):554-557
pubmed: 35852386
BMC Cardiovasc Disord. 2015 Sep 23;15:103
pubmed: 26399240
BMJ Open. 2022 May 15;12(5):e059716
pubmed: 35569825
Med J Aust. 2007 Jun 4;186(11):560-3
pubmed: 17547543
BMC Public Health. 2014 Feb 25;14:201
pubmed: 24568143
Stroke. 2013 Jul;44(7):2064-89
pubmed: 23652265
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
J Am Coll Cardiol. 2001 Dec;38(7):2101-13
pubmed: 11738322
J Am Heart Assoc. 2015 Jul 28;4(7):
pubmed: 26219562
J Am Soc Echocardiogr. 2019 Jan;32(1):1-64
pubmed: 30282592
Int J Equity Health. 2020 May 7;19(1):64
pubmed: 32381081